Standard BioTools Inc.
DB:FLB Rapporto sulle azioni
Standard BioTools Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Standard BioTools ha un patrimonio netto totale di $489.3M e un debito totale di $55.2M, che porta il suo rapporto debito/patrimonio netto a 11.3%. Le sue attività totali e le sue passività totali sono rispettivamente $681.5M e $192.2M.
Informazioni chiave
11.3%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti US$366.33m Patrimonio netto US$489.33m Totale passività US$192.21m Totale attività US$681.54m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024
Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.073 loss per share (vs US$0.27 loss in 3Q 2023) Nov 01
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
No longer forecast to breakeven Aug 02
Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024 Aug 02
New major risk - Share price stability Aug 01
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.22 loss in 2Q 2023) Aug 01
Standard BioTools Inc. Announces Chief Financial Officer Changes Aug 01
High number of new and inexperienced directors Jul 25
Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Standard BioTools Inc., Annual General Meeting, Jun 27, 2024 May 24
Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024 May 10
Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 27 Standard BioTools Inc. Announces Operational Restructuring Plan Apr 26
Now 23% overvalued after recent price rise Apr 12
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging Apr 09
Forecast to breakeven in 2026 Mar 03
New major risk - Financial position Mar 01
Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024 Mar 01
Full year 2023 earnings released: US$0.94 loss per share (vs US$2.43 loss in FY 2022) Feb 29
Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
New major risk - Revenue and earnings growth Jan 09
Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023 Jan 09 SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.
Third quarter 2023 earnings released: US$265 loss per share (vs US$0.37 loss in 3Q 2022) Nov 09
Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26 SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 06
SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 05
Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.82 loss in 2Q 2022) Aug 09
Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
High number of new directors Jun 21
Senior VP & CFO recently bought €179k worth of stock May 23
Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System May 19 Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer
First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022) May 11
Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors May 05
Standard BioTools Inc. Provides Earnings Guidance for the Year 2023 Feb 16
Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021) Feb 16
Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023 Feb 01
Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer Jan 04
Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares. Nov 29
Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) Nov 10
Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform Oct 07
Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021) Aug 10
Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022 Aug 10
Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary Jul 09
Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations Jun 29
Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index Jun 26
First quarter 2022 earnings released: US$0.99 loss per share (vs US$0.25 loss in 1Q 2021) May 07
Standard BioTools Inc., Annual General Meeting, Jun 15, 2022 May 02
Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 23
Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging Apr 12 Fluidigm Corporation Announces Board Changes
Fluidigm Corporation Announces Management Changes Mar 30
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.083 loss in 3Q 2020) Nov 09
Fluidigm Corporation Announces the Publication of New Data Further Validating the Potential of Its Mass Cytometry Technologies Sep 01
Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.18 loss in 2Q 2020) Aug 08 Fluidigm Corporation Revises Earnings Guidance for the Fiscal Year 2021
Fluidigm Corporation Announces Launch of CyTOF XT May 26
First quarter 2021 earnings released: US$0.25 loss per share (vs US$0.23 loss in 1Q 2020) May 08 Fluidigm Corporation Provides Revenue Guidance for the Second Quarter of 2021
Fluidigm Corporation Announces FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay Mar 03
Full year 2020 earnings released: US$0.74 loss per share (vs US$0.97 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
Full year 2020 earnings released: US$0.74 loss per share (vs US$0.97 loss in FY 2019) Feb 13
Revenue misses expectations Feb 13
Fluidigm Corporation Announces Collaboration with Zhejiang Puluoting Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China Feb 11
New 90-day high: €5.95 Feb 11
Fluidigm Corporation Announces Fluidigm® Mass Cytometry Technology and the Maxpar® Direct™ Immune Profiling Assay™ Feb 10
Fluidigm Corporation Announces That Helix Specialty Diagnostics Is Partnering with Genomic LTC DX to Provide Covid-19 Testing Using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD System Jan 28
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $453.6M ) di FLB superano le sue passività a breve termine ( $120.6M ).
Passività a lungo termine: Le attività a breve termine di FLB ( $453.6M ) superano le sue passività a lungo termine ( $71.6M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: FLB ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di FLB si è ridotto da 30.7% a 11.3% negli ultimi 5 anni.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: FLB ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero .
Previsione Cash Runway: FLB ha una liquidità sufficiente per più di 3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 26.9 % ogni anno
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}